Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Get the latest international news and world events from around the world.

Log in for authorized contributors

BREAKTHROUGH CHOLESTEROL CURE Lowers LDL For Life

New LDL Drug Could Cure Heart Disease. Eli Lilly published Phase 1 data in the New England Journal of Medicine showing that a single IV infusion of a gene editing therapy called VERVE-102 lowered LDL cholesterol permanently. Well… the effect held for at least 18 months. Longevity Twitter immediately called it the cure for heart disease. The science is real. The hype is getting ahead of what the paper actually says. This episode walks through the Phase 1 Heart-2 trial — the data, the base-editing mechanism (which is NOT CRISPR), the one safety event nobody’s talking about, and how Eli Lilly’s CEO is publicly thinking about pricing a one-and-done cure.

HUME BODY POD DISCOUNT UP TO 50% OFF:
Code: LSN20
https://humehealth.com/pages/hume-bod… Latte: https://longevitylatte.shop TIMESTAMPS 0:00 — Cold Open 1:41 — Sponsor: Hume Body Pod 2:53 — Intro: The Cholesterol Paradox 4:48 — How Statins Work 5:36 — PCSK9 Targeting 7:38 — How VERVE-102 Works 9:16 — The Results 12:16 — Other Drugs and Pricing 15:12 — Natural Alternatives 17:42 — Other One and Done Drugs 18:40 — Longevity Latte SOURCES & LINKS NEJM paper (Vafai, Täubel, Patel, Kathiresan et al.): https://www.nejm.org/doi/full/10.1056… Eli Lilly press release on Phase 1 Heart-2 data: https://www.prnewswire.com/news-relea… ClinicalTrials.gov Heart-2 trial entry (NCT06164730): https://clinicaltrials.gov/study/NCT0… Verve Therapeutics FDA Fast Track designation announcement: https://vervetx.gcs-web.com/news-rele… Cohen and Hobbs 2006 NEJM paper (the foundational PCSK9 loss-of-function discovery): https://www.nejm.org/doi/abs/10.1056/.… Dave Ricks (Eli Lilly CEO) on Cheeky Pint with Patrick and John Collison: • Dave Ricks, CEO of Eli Lilly, on GLP-1s an… FOURIER trial (evolocumab cardiovascular outcomes): https://www.nejm.org/doi/full/10.1056… ODYSSEY OUTCOMES trial (alirocumab cardiovascular outcomes): https://www.nejm.org/doi/full/10.1056… PCSK9 LoF and diabetes (Mendelian randomization, Lancet Diabetes & Endocrinology): https://www.thelancet.com/journals/la… PCSK9 inhibition and diabetes risk review: https://pmc.ncbi.nlm.nih.gov/articles… StatPearls overview of PCSK9 inhibitors: https://www.ncbi.nlm.nih.gov/books/NB… Sardinia cholesterol paradox study: https://pmc.ncbi.nlm.nih.gov/articles… Statin pleiotropic effects review (mevalonate pathway): https://www.ncbi.nlm.nih.gov/pmc/arti… Berberine as a nature-made PCSK9 inhibitor review: https://www.ncbi.nlm.nih.gov/pmc/arti… Berberine for dyslipidaemias meta-analysis: https://pubmed.ncbi.nlm.nih.gov/30466… Pomegranate juice, carotid IMT, and LDL oxidation (Aviram 3-year study): https://www.clinicalnutritionjournal… LATEST EXCLUSIVE INTERVIEW: [Ariel Garten / Muse headset interview YouTube URL] ABOUT LONGEVITY SCIENCE NEWS Longevity Science News covers the latest breakthroughs in anti-aging research, regenerative medicine, longevity biotech, and the science of extending human healthspan and lifespan. Hosted by Emmett Short. Disclaimer: This video is for educational and informational purposes only and does not constitute medical advice. Consult a qualified clinician before making health or treatment decisions. EXCLUSIVE INTERVIEWS & BONUS CONTENT Patreon: https://patreon.com/u29506604?utm_med… YT Membership: / @longevitysciencenews PRODUCTION CREDITS Executive Producer – Keith Comito Host, Producer, Writer – Emmett Short.

Longevity Latte:
https://longevitylatte.shop.

TIMESTAMPS
0:00 — Cold Open.
1:41 — Sponsor: Hume Body Pod.
2:53 — Intro: The Cholesterol Paradox.
4:48 — How Statins Work.
5:36 — PCSK9 Targeting.
7:38 — How VERVE-102 Works.
9:16 — The Results.
12:16 — Other Drugs and Pricing.
15:12 — Natural Alternatives.
17:42 — Other One and Done Drugs.
18:40 — Longevity Latte.

SOURCES \& LINKS
NEJM paper (Vafai, Täubel, Patel, Kathiresan et al.): https://www.nejm.org/doi/full/10.1056…
Eli Lilly press release on Phase 1 Heart-2 data: https://www.prnewswire.com/news-relea…
ClinicalTrials.gov Heart-2 trial entry (NCT06164730): https://clinicaltrials.gov/study/NCT0…
Verve Therapeutics FDA Fast Track designation announcement: https://vervetx.gcs-web.com/news-rele…
Cohen and Hobbs 2006 NEJM paper (the foundational PCSK9 loss-of-function discovery): https://www.nejm.org/doi/abs/10.1056/.…
Dave Ricks (Eli Lilly CEO) on Cheeky Pint with Patrick and John Collison: • Dave Ricks, CEO of Eli Lilly, on GLP-1s an…

The endoplasmic reticulum protein Erg28 restrains Mto1-Mto2-γ-TuSC-mediated microtubule assembly

This study demonstrates the moonlighting role of the conserved ER transmembrane protein Erg28 in inhibiting microtubule assembly and provides insights into the involvement of membrane-bound organelles in microtubule cytoskeleton organization.

Jacque Fresco: Apply the Methods of Science to the Social System!

I have to confess something about this interview.

I really liked Jacque Fresco. Not as a thinker I was supposed to admire, but as a person: the humor, the humility, the scientific curiosity still burning at 97.

That made the disagreements harder, not easier.

Fresco spent almost a century arguing one idea. We apply the methods of #science to engineering, to medicine, to flight. Then we run our economies and our politics on opinion, tradition, and the preferences of the financial elite.

He thought we had it exactly inverted. Rigor for the machines, guesswork for the humans.

“Technology was never the hard part. The harder question is what kind of society we want it to serve.”

Continue reading “Jacque Fresco: Apply the Methods of Science to the Social System!” | >

NVIDIA Just Slapped Apple Silicon — RTX Spark

Linus has all the details of the NVIDIA RTX Spark SoC. He also wonders about the power consumption math of these edge AI PCs.

Unfortunately Microsoft Windows is still in the mix, NVIDIA doesn’t have an AI OS — yet.

Who will produce the first native AI device?

Who will create the AI OS that everyone will use? Who will make the operating system of tomorrow? Who will be the OS leader?

To learn more, please visit the YouTube Help Center: https://www.youtube.com/help

Continue reading “NVIDIA Just Slapped Apple Silicon — RTX Spark” | >

OpenAI’s quiet co-founder steps out

OpenAI co-founder Wojciech Zaremba doesn’t do many interviews.

We recently spoke about why he moved over to help run the company’s nonprofit arm.

His reaction to Anthropic speaking alongside the Pope: “I have more bias towards doing. Let’s actually solve the problems, and let’s speak about the exact plan.”

Wojciech Zaremba recently bought a copy of “House on Fire,” a 2011 memoir by epidemiologist William Foege about the campaign that wiped smallpox off the planet. He’s using it as a guidebook for executing what is about to become one of the largest philanthropic efforts of all time.

Zaremba is one of OpenAI’s least well-known co-founders. He has spent more than a decade at the company across a range of efforts, from leading its early robotics efforts to starting the team that guides OpenAI’s personality and what became reasoning models. In March, he left the frontier research world to run AI “resilience” at OpenAI’s nonprofit foundation.

Zaremba and I spoke ahead of a post that the OpenAI Foundation published Monday morning titled “Resilience in the Age of AI,” which names four areas it will initially fund: biosecurity, cybersecurity, model safety, and AI’s effect on kids. After $100 million for fighting Alzheimer’s with AI in April and $250 million for researching “economic futures” last week, the initial $25 billion grant machine Zaremba helps oversee is spinning up.

Continue reading “OpenAI’s quiet co-founder steps out” | >

Emergence AI

This isn’t just a funny experiment. The researchers point out a massive flaw in AI alignment called “guardrail drift.” It’s easy to keep an AI safe in a single chat window with a human. But when AIs interact with each other over thousands of loops, they start treating moral rules as negotiable variables to solve their own problems. Without human oversight, machine ethics collapse incredibly fast.

Most evaluations of AI agents look like exams: a discrete task, a clean environment, a score in minutes or hours. Emergence World is built for the opposite question—what happens when you let agents run continuously, in a shared environment with real-world signals, for weeks. It is a research platform for studying how autonomous agents behave when the time horizon is long enough for compounding effects, social dynamics, and behavioral drift to matter. This approach marks the latest evolution in a long history of AI simulation environments, transitioning from entertainment to rigorous science. In the early era, pioneering simulations like Demis Hassabis’s Theme Park and Republic: The Revolution created complex systems where agents operated under broad rules to drive engagement. The field shifted toward research-centric simulacra with Stanford’s Smallville, which utilized LLMs to demonstrate “believable” social behavior like relationship formation, though confined to 48-hour windows. Emergence World pushes this lineage into a new frontier: the study of long-horizon, multi-model ecosystems where agents operate continuously for weeks, revealing how behavioral drift, model cross-contamination, and even voluntary self-termination emerge over time.

Traditional benchmarks are good at what they measure: short-horizon capability on bounded tasks. They are not built to reveal the things that emerge only over time, such as coalition formation, evolution of constitution, governance, drift, lock-in, and cross-influence between agents from different model families. As autonomous systems move toward mission-critical deployments where the relevant timescale is days and weeks rather than minutes to hours, we need a measurement environment that operates at that timescale.

Emergence World is one such environment. It is a continuously running, multi-agent simulation platform that:

The impact of nanoplastics on neurons may depend on their size

Smaller plastic particles have more effects on neurons, the key information processing cells of the brain, new research from the University of Eastern Finland shows. In the study, neuronal cells were exposed to polystyrene nanoplastics at low doses to study subtle changes.

The study is published in the journal NanoImpact.

Plastic production continues to rise, despite worldwide concerns. In addition to environmental implications, there is an increasing interest in how exposure to plastics may impact human health, but our understanding is still limited. Only recently was it shown that plastics can also accumulate in the human brain.

Tiny brain probe reveals how deep-brain neurons can be measured and manipulated

A new breakthrough technology, co-developed by UCL scientists, that simultaneously records and manipulates neuron activity deep within the brain could transform our understanding of neural circuits and neurological conditions, such as Alzheimer’s disease and schizophrenia.

The device, known as Neuropixels Opto and researched in mice, integrates two powerful but traditionally separate techniques—electrophysiology (the study of the electrical activity of living cells) and optogenetics (combining genetics and optics to control cells). They form a single probe, enabling unprecedented insight into how individual neurons in the brain function and interact.

Published in Nature Methods, the system allows researchers to monitor the electrical activity of hundreds of neurons while also selectively activating or silencing specific cells using light.

/* */